Table 2. Vaccine Doses Administered to the Surveillance Population, December 14, 2020-June 26, 2021.
BNT162b2 (N) | mRNA-1273 (N) | Both mRNA vaccines (N) | Surveillance population ≥12 y, No.a | |||||
---|---|---|---|---|---|---|---|---|
Dose 1 | Dose 2 | Dose 1 | Dose 2 | Dose 1 | Dose 2 | Total doses | ||
Total | 3 539 611 | 3 214 737 | 2 636 202 | 2 454 578 | 6 175 813 | 5 669 315 | 11 845 128 | 10 162 227 |
Sex | ||||||||
Female | 1 909 585 | 1 738 663 | 1 435 437 | 1 341 000 | 3 345 022 | 3 079 663 | 6 424 685 | 5 326 063 |
Male | 1 630 026 | 1 476 074 | 1 200 765 | 1 113 578 | 2 830 791 | 2 589 652 | 5 420 443 | 4 836 164 |
Age group, y | ||||||||
12-15 | 213 814 | 152 494 | 0 | 0 | 213 814 | 152 494 | 366 308 | 558 130 |
16-17 | 139 660 | 120 488 | 0 | 0 | 139 660 | 120 488 | 260 148 | 280 784 |
18-49 | 1 624 340 | 1 468 324 | 1 171 064 | 1 065 998 | 2 795 404 | 2 534 322 | 5 329 726 | 5 124 940 |
50-64 | 816 597 | 760 201 | 719 892 | 676 251 | 1 536 489 | 1 436 452 | 2 972 941 | 2 329 719 |
65-74 | 438 496 | 417 945 | 450 819 | 429 666 | 889 315 | 847 611 | 1 736 926 | 1 139 752 |
≥75 | 306 704 | 295 285 | 293 929 | 282 290 | 600 633 | 577 575 | 1 178 208 | 728 902 |
Race and ethnicity | ||||||||
American Indian/Alaska Native | 10 296 | 9295 | 8349 | 7675 | 18 645 | 16 970 | 35 615 | 31 430 |
Asian | 576 803 | 528 677 | 364 432 | 343 035 | 941 235 | 871 712 | 1 812 947 | 1 234 172 |
Black, non-Hispanic | 184 621 | 163 717 | 150 120 | 137 608 | 334 741 | 301 325 | 636 066 | 668 516 |
Hispanic/Latino | 767 978 | 679 008 | 616 513 | 567 361 | 1 384 491 | 1 246 369 | 2 630 860 | 2 509 139 |
Native Hawaiian/Pacific Islander | 22 858 | 20 562 | 16 053 | 14 856 | 38 911 | 35 418 | 74 329 | 61 880 |
White, non-Hispanic | 1 477 545 | 1 368 800 | 1 148 149 | 1 080 562 | 2 625 694 | 2 449 362 | 5 075 056 | 4 130 350 |
Multiple/otherb | 123 770 | 111 871 | 88 600 | 82 433 | 212 370 | 194 304 | 406 674 | 338 984 |
Unknown | 375 740 | 332 807 | 243 986 | 221 048 | 619 726 | 553 855 | 1 173 581 | 1 187 756 |
Total enrolled population that has Emergency Use Authorization for existing COVID-19 vaccines. All enrolled persons aged 12 years or older are included in the weekly COVID-19 vaccine surveillance.
Includes persons with more than 1 non-Hispanic race and ethnicity and all other non-Hispanic races and ethnicities.